Cargando…
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
BACKGROUND: Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcinoma, but no targeted therapies have been approved. Immune checkpoint inhibitors...
Autores principales: | Mou, Haibo, Yu, Lanfang, Liao, Qin, Hou, Xuehua, Wu, Yinfang, Cui, Qiang, Yan, Na, Ma, Ruobing, Wang, Lingjian, Yao, Ming, Wang, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233589/ https://www.ncbi.nlm.nih.gov/pubmed/30419854 http://dx.doi.org/10.1186/s12885-018-5021-2 |
Ejemplares similares
-
Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia
por: Wang, Luo, et al.
Publicado: (2023) -
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021) -
Cholangiocarcinoma in the Era of Immunotherapy
por: Manthopoulou, Eleni, et al.
Publicado: (2023) -
Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022) -
Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)